JP2017520619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520619A5 JP2017520619A5 JP2017514990A JP2017514990A JP2017520619A5 JP 2017520619 A5 JP2017520619 A5 JP 2017520619A5 JP 2017514990 A JP2017514990 A JP 2017514990A JP 2017514990 A JP2017514990 A JP 2017514990A JP 2017520619 A5 JP2017520619 A5 JP 2017520619A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tablet
- ceritinib
- weight percent
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 22
- 229960001602 ceritinib Drugs 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000005550 wet granulation Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229920001531 copovidone Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004359P | 2014-05-29 | 2014-05-29 | |
| US62/004,359 | 2014-05-29 | ||
| PCT/IB2015/053966 WO2015181739A1 (en) | 2014-05-29 | 2015-05-27 | Ceritinib formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020046475A Division JP7084955B2 (ja) | 2014-05-29 | 2020-03-17 | セリチニブ製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520619A JP2017520619A (ja) | 2017-07-27 |
| JP2017520619A5 true JP2017520619A5 (enExample) | 2018-07-05 |
| JP6679578B2 JP6679578B2 (ja) | 2020-04-15 |
Family
ID=53298568
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514990A Active JP6679578B2 (ja) | 2014-05-29 | 2015-05-27 | セリチニブ製剤 |
| JP2020046475A Active JP7084955B2 (ja) | 2014-05-29 | 2020-03-17 | セリチニブ製剤 |
| JP2022034913A Withdrawn JP2022078236A (ja) | 2014-05-29 | 2022-03-08 | セリチニブ製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020046475A Active JP7084955B2 (ja) | 2014-05-29 | 2020-03-17 | セリチニブ製剤 |
| JP2022034913A Withdrawn JP2022078236A (ja) | 2014-05-29 | 2022-03-08 | セリチニブ製剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US20170112834A1 (enExample) |
| EP (1) | EP3148513B1 (enExample) |
| JP (3) | JP6679578B2 (enExample) |
| KR (1) | KR20170008239A (enExample) |
| CN (1) | CN106456640B (enExample) |
| AR (1) | AR100625A1 (enExample) |
| AU (3) | AU2015265470A1 (enExample) |
| BR (1) | BR112016027580A8 (enExample) |
| CA (1) | CA2948291A1 (enExample) |
| CL (1) | CL2016003047A1 (enExample) |
| DK (1) | DK3148513T3 (enExample) |
| EA (1) | EA036922B1 (enExample) |
| EC (1) | ECSP16096826A (enExample) |
| ES (1) | ES2792574T3 (enExample) |
| HU (1) | HUE048950T2 (enExample) |
| IL (1) | IL248835B (enExample) |
| MX (1) | MX373624B (enExample) |
| PE (1) | PE20170313A1 (enExample) |
| PH (1) | PH12016502272A1 (enExample) |
| PL (1) | PL3148513T3 (enExample) |
| PT (1) | PT3148513T (enExample) |
| SG (1) | SG11201609208UA (enExample) |
| SI (1) | SI3148513T1 (enExample) |
| TN (1) | TN2016000484A1 (enExample) |
| TW (1) | TWI721946B (enExample) |
| UY (1) | UY36140A (enExample) |
| WO (1) | WO2015181739A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI721946B (zh) | 2014-05-29 | 2021-03-21 | 瑞士商諾華公司 | 色瑞替尼調配物 |
| CN106176752B (zh) * | 2015-05-07 | 2020-06-23 | 石药集团中奇制药技术（石家庄）有限公司 | 色瑞替尼药物组合物 |
| CN109381440A (zh) * | 2018-11-15 | 2019-02-26 | 威海贯标信息科技有限公司 | 一种艾乐替尼组合物 |
| CN113244236B (zh) * | 2021-06-01 | 2023-02-03 | 上海市第一人民医院 | 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3632778A (en) * | 1970-06-10 | 1972-01-04 | Hoffmann La Roche | Tablets containing l-dopa |
| TW200803850A (en) * | 2006-03-06 | 2008-01-16 | Wyeth Corp | Tablet formulations and processes |
| US20090239920A1 (en) | 2006-11-21 | 2009-09-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080175901A1 (en) | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| JP5208123B2 (ja) * | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| EA019941B1 (ru) * | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| EP2090297A1 (en) | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
| ES2377869T3 (es) | 2008-09-04 | 2012-04-02 | Cargill, Incorporated | Fabricación de comprimidos de eritritol |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| CN102480998B (zh) | 2009-08-18 | 2016-05-25 | 卡吉尔公司 | 赤藓醇和异麦芽酮糖醇的压片 |
| JP5596799B2 (ja) | 2010-05-11 | 2014-09-24 | 田辺三菱製薬株式会社 | カナグリフロジン含有錠剤 |
| CN103200828A (zh) | 2010-09-07 | 2013-07-10 | 卡吉尔公司 | 固体化糖醇混合物 |
| TWI721946B (zh) | 2014-05-29 | 2021-03-21 | 瑞士商諾華公司 | 色瑞替尼調配物 |
-
2015
- 2015-05-27 TW TW104117053A patent/TWI721946B/zh not_active IP Right Cessation
- 2015-05-27 AR ARP150101661A patent/AR100625A1/es unknown
- 2015-05-27 BR BR112016027580A patent/BR112016027580A8/pt not_active Application Discontinuation
- 2015-05-27 ES ES15727470T patent/ES2792574T3/es active Active
- 2015-05-27 SI SI201531221T patent/SI3148513T1/sl unknown
- 2015-05-27 US US15/313,367 patent/US20170112834A1/en not_active Abandoned
- 2015-05-27 DK DK15727470.5T patent/DK3148513T3/da active
- 2015-05-27 AU AU2015265470A patent/AU2015265470A1/en not_active Abandoned
- 2015-05-27 HU HUE15727470A patent/HUE048950T2/hu unknown
- 2015-05-27 WO PCT/IB2015/053966 patent/WO2015181739A1/en not_active Ceased
- 2015-05-27 PT PT157274705T patent/PT3148513T/pt unknown
- 2015-05-27 SG SG11201609208UA patent/SG11201609208UA/en unknown
- 2015-05-27 CA CA2948291A patent/CA2948291A1/en not_active Abandoned
- 2015-05-27 PE PE2016002399A patent/PE20170313A1/es not_active Application Discontinuation
- 2015-05-27 UY UY0001036140A patent/UY36140A/es not_active Application Discontinuation
- 2015-05-27 JP JP2017514990A patent/JP6679578B2/ja active Active
- 2015-05-27 PL PL15727470T patent/PL3148513T3/pl unknown
- 2015-05-27 CN CN201580028582.7A patent/CN106456640B/zh active Active
- 2015-05-27 EP EP15727470.5A patent/EP3148513B1/en active Active
- 2015-05-27 MX MX2016015736A patent/MX373624B/es active IP Right Grant
- 2015-05-27 EA EA201692310A patent/EA036922B1/ru not_active IP Right Cessation
- 2015-05-27 TN TN2016000484A patent/TN2016000484A1/en unknown
- 2015-05-27 KR KR1020167032886A patent/KR20170008239A/ko not_active Ceased
-
2016
- 2016-11-08 IL IL248835A patent/IL248835B/en active IP Right Grant
- 2016-11-15 PH PH12016502272A patent/PH12016502272A1/en unknown
- 2016-11-28 CL CL2016003047A patent/CL2016003047A1/es unknown
- 2016-12-28 EC ECIEPI201696826A patent/ECSP16096826A/es unknown
-
2018
- 2018-05-01 AU AU2018203007A patent/AU2018203007B2/en not_active Ceased
- 2018-09-26 US US16/142,263 patent/US20190022095A1/en not_active Abandoned
-
2019
- 2019-09-16 US US16/571,229 patent/US11000523B2/en active Active
- 2019-09-20 AU AU2019232937A patent/AU2019232937B2/en not_active Ceased
-
2020
- 2020-03-17 JP JP2020046475A patent/JP7084955B2/ja active Active
-
2021
- 2021-02-05 US US17/168,265 patent/US12357630B2/en active Active
-
2022
- 2022-03-08 JP JP2022034913A patent/JP2022078236A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014167026A5 (enExample) | ||
| JP2015511635A5 (enExample) | ||
| US9770437B2 (en) | Compositions of eltrombopag | |
| FI3182975T3 (fi) | Rukaparibin suuren annosvahvuuden tabletteja | |
| NZ602075A (en) | Abuse-resistant formulations | |
| JP2016528302A5 (enExample) | ||
| JP2009545560A5 (enExample) | ||
| JP2016513724A5 (enExample) | ||
| JP2018517676A5 (enExample) | ||
| JP2010132654A5 (enExample) | ||
| JP2017537168A5 (enExample) | ||
| HRP20240564T1 (hr) | Novi farmaceutski sastav | |
| JP2015509539A5 (enExample) | ||
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| JP2015510916A5 (enExample) | ||
| JP2017523149A5 (enExample) | ||
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| JP2017502948A5 (enExample) | ||
| WO2015110952A1 (en) | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof | |
| JP2016530238A5 (enExample) | ||
| RU2016150178A (ru) | Твёрдая дисперсия аллисартана изопроксила и фармацевтическая композиция | |
| JP6446511B2 (ja) | 非晶質体ソリフェナシン及び抗酸化剤を含有する固形製剤 | |
| JP2022078236A (ja) | セリチニブ製剤 | |
| JP2015120758A5 (enExample) | ||
| JP2012515757A (ja) | トリメタジジンの放出調節固形薬剤組成物及びその製造方法 |